
OTLK Stock Forecast & Price Target
OTLK Analyst Ratings
Bulls say
Outlook Therapeutics is attractive because it has already secured marketing authorization for LYTENAVA in the European Union and United Kingdom, validating ONS-5010 clinically and commercially while creating an initial revenue base that is still early but expanding. The company’s FDA appeal win in May 2026 and BLA resubmission on June 1, 2026 materially de-risk the U.S. story, with a decision expected within 60 days and management preparing for a U.S. launch by the end of calendar 2026. With about $62.3 million in pro forma cash, $50 million to $75 million of first-year U.S. sales expected, and a path to more than $500 million in annual U.S. sales by 2030, the business has meaningful operating leverage if adoption and reimbursement progress as planned.
Bears say
Outlook Therapeutics is facing a deeply challenged approval path for ONS-5010, as the FDA issued Complete Response Letters on August 30, 2023, August 28, 2025, and December 31, 2025, despite the NORSE TWO pivotal trial meeting its safety and efficacy endpoints. The repeated setbacks reflect persistent regulatory and CMC concerns, with the most recent CRL citing a lack of substantial evidence of effectiveness and recommending additional confirmatory evidence, underscoring material execution risk around product approval and commercialization. Combined with balance sheet and liquidity risk, reimbursement uncertainty, and heavy competition in wet AMD, the company remains highly dependent on future regulatory success to justify its investment case.
This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OTLK Analyst Forecast & Price Prediction
Start investing in OTLK
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Outlook Therapeutics Inc (OTLK) Forecast
OTLK Analyst Forecast & Price Prediction
Start investing in OTLK
Order type
Buy in
Order amount
Est. shares
0 shares